Allison Transmission Receives Certification from California Air Resources Board for Model Year 2021 Electric Hybrid Propulsion System Paired with Cummins Engines streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Provided by Business Wire
Apr 23, 2021 11:59 AM UTC
LEO Pharma Receives Positive CHMP Opinion of Adtralza® (tralokinumab) for the Treatment of Adults With Moderate-to-Severe Atopic Dermatitis
NOT FOR DISTRIBUTION IN THE UK OR IRELAND
If authorized, Adtralza® (tralokinumab) will be the first approved biologic that specifically targets the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms1,2
The CHMP opinion is primarily supported by data from ECZTRA 1, 2, and 3 trials included in the Marketing Authorization Application
LEO Pharma A/S, a global leader in medical dermatology, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting a marketing authorization of Adtralza® (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.
LEO Pharma Receives Positive CHMP Opinion of Adtralza (tralokinumab) for the Treatment of Adults With Moderate-to-Severe Atopic Dermatitis
If authorized, Adtralza (tralokinumab) will be the first approved biologic that specifically targets the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms
1,2
The CHMP opinion is primarily supported by data from ECZTRA 1, 2, and 3 trials included in the Marketing Authorization Application
LEO Pharma A/S, a global leader in medical dermatology, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting a marketing authorization of Adtralza
Posted on 205
Allison Transmission, a leading designer and manufacturer of vehicle propulsion solutions for commercial and defense vehicles, the largest global manufacturer of medium and heavy-duty fully automatic transmissions, and a leader in electrified propulsion systems, is pleased to announce that the eGen Flex™, its next generation electric hybrid propulsion solution, will be put into revenue service at New York City Transit (NYCT) in May.
Allison Transmission’s eGen Flex, its next generation electric hybrid propulsion solution, will be put into revenue service at New York City Transit (NYCT) in May (Photo: Business Wire)
The electric hybrid system from Allison offers revolutionary capabilities and fully electric propulsion when customers need it, without the added infrastructure requirements of full electrification. The eGen Flex system includes full electric drive capability for up to 10 miles, depending u
Allison Transmission and Emergency One Formalize Collaboration on Electric Axle Integration
Allison Transmission, a leading designer and manufacturer of conventional, hybrid and electric vehicle propulsion solutions, in collaboration with Emergency One (UK) Ltd, the market leader in the United Kingdom in the manufacture, service and support of fire and rescue vehicles, is pleased to announce a strategic Memorandum of Understanding (MoU). The two companies will integrate the Allison eGen Power 100D electric axle into Emergency One s fire rescue and emergency vehicle platform as part of this MoU. This builds on the successful relationship to date, where 90% of the units Emergency One sells are equipped with an Allison fully automatic transmission.